Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

HOST GENETIC VARIATION IN THE TNF AND NF‐ĸB PATHWAYS AND PROGNOSIS IN MANTLE CELL LYMPHOMA: AN ANALYSIS OF 2 STUDIES
Wang, Y., Wang, S.S., Inwards, David J. , Rothman, Nathaniel , Wang, Yucai , Habermann, Thomas M. , Maurer, Matthew J. , Link, Brian K. , Feldman, Andrew L. , Witzig, Thomas E. , Cozen, Wendy , Morton, Lindsay M. , Chanock, Stephen Jacob , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 151-152

10.1002/hon.2438_4 Get It

Consumer Perspectives on Access to Direct‐to‐Consumer Genetic Testing: Role of Demographic Factors and the Testing Experience
Gollust, Sarah E. , Gray, Stacy W. , Carere, Deanna Alexis , Koenig, Barbara A. , McGuire, Amy , Sharp, Richard R. , Spector‐Bagdady, Kayte , Wang, Na , Roberts, J. Scott , Group, for the PGen Study, Roberts, J. Scott , Lehmann, Lisa Soleymani , Green, Robert C. , Group, for the PGen Study, Sharp, Richard R , Gray, Stacy W

Mayo Clinic

The Milbank Quarterly | June 7, 2017 | Volume: 95 | Issue: 2 | Pages: 291-318

10.1111/1468-0009.12262 | PMID 28589610 Get It

Policy Points: The policy context of direct‐to‐consumer personal genomic testing (DTC‐PGT) has been evolving over the last decade, with little empirical data available about consumers’ perspectives. A majority of consumers of DTC‐PGT supported expanded access to services and their integration into the medical context and opposed more governmental regulation. Consumers’ attitudes about access to services and regulation did not vary based on the specific genetic risk information they received from companies, but may vary based on whether consumers perceived their DTC experience negatively. ContextWhile policymakers have been considering the appropriateness of direct‐to‐consumer personal genomic testing (DTC‐PGT) for more than a decade, there is little empirical data on consumers’ views regarding the regulation of these products. No research has assessed whether consumers’ personal experience with testing is related to their views about access to and regulation of DTC tests.MethodsData were analyzed from the PGen Study, a longitudinal prospective cohort of DTC‐PGT customers of 23andMe (n = 564) and Pathway Genomics (n = 377; total N = 941). Consumers were sent an electronic survey before receiving genetic test results and again 6 months after receipt of results.FindingsAt the 6‐month follow‐up, more than 80% of participants believed that people have a right to access genetic information directly, that parents should be able to get DTC‐PGT testing for their children, and that genetic information should be kept private. Participants supported health insurance coverage of PGT (60%), wider availability of PGT (68%), and inclusion of genetic information in medical records (63%). Participants were less supportive of government regulation (28%) and restricting testing to clinical settings (14%). Conservative political ideology was associated with less support for government regulation (P < 0.001), as was feeling more confident in one's genetic knowledge (P < 0.05). Participants’ level of computed genetic risk for common diseases, as indicated by their actual test results received from companies, showed no relationship with attitudes. However, those who perceived that they had received elevated risk results expressed lower support for expanded availability and incorporation of PGT into health care (P < 0.01). Those who reported being upset by their genetic test results were less likely to endorse access to DTC products without a medical professional (P < 0.01).ConclusionsPGT consumers supported expanded access to these services and opposed additional regulation. Users who had a negative personal experience with PGT testing were less supportive of expanded availability without a medical professional.
Secretory diarrhea and hypokalemia associated with colonic pseudo‐obstruction: A case study and systematic analysis of the literature
Haffar, Samir , Szarka, Lawrence A., Murad, M. Hassan , Camilleri, Michael , Camilleri, M , Bazerbachi, Fateh , Wang, Zhen , Prokop, Larry J. , Murad, M Hassan

Mayo Clinic

Neurogastroenterology & Motility | June 5, 2017 | Volume: 29 | Issue: 11 | Pages: No page available

10.1111/nmo.13120 | PMID 28580600 Get It

AbstractBackgroundColonic pseudo‐obstruction (CPO) is characterized by colonic distention in the absence of mechanical obstruction or toxic megacolon. Concomitant secretory diarrhea (SD) with hypokalemia (SD‐CPO) due to gastrointestinal (GI) loss requires further characterization.AimTo perform a systematic review of SD‐CPO, report a case study, and compare SD‐CPO with classical CPO (C‐CPO).MethodsWe performed a search of MEDLINE, EMBASE, Cochrane, and Scopus for reports based on a priori criteria for CPO, SD and GI loss of potassium. An additional case at Mayo Clinic was included.ResultsNine publications met inclusion criteria, with a total of 14 cases. Six studies had high, three moderate, and our case high methodological quality. Median age was 74 years (66‐97), with 2:1 male/female ratio. Kidney disease was present in 6/14 patients. Diarrhea was described as profuse, watery, or viscous in 10 patients. Median serum, stool, and urine potassium concentrations (mmol/L) were 2.4 (range: 1.9‐3.1), 137 (100‐180), and 17 (8‐40), respectively. Maximal diameter of colon and cecum (median) were 10.2 cm and 10.5 cm, respectively. Conservative therapy alone was effective in five out of 14 patients. Median potassium supplementation was 124 mEq/d (40‐300). Colonic decompression was effective in three out of six patients; one had a total colectomy; three out of 14 had died. The main differences between SD‐CPO and C‐CPO were lower responses to treatments: conservative measures (35.7% vs 73.6%, P=.01), neostigmine (17% vs 89.2%, P<.001), and colonic decompression (50% vs 82.4%, P=.02).ConclusionSD‐CPO is a rare phenotype associated with increased fecal potassium and is more difficult to treat than C‐CPO.
Clinical commentary on ‘Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: Two new cases’, by Wang et al.
Flanagan, Eoin P.

Mayo Clinic

Multiple Sclerosis Journal | June 5, 2017 | Volume: 23 | Issue: 14 | Pages: 1954-1955

10.1177/1352458517712867 | PMID 28580877 Get It

Identification of fucosylated Fetuin‐A as a potential biomarker for cholangiocarcinoma
Betesh, Lucy, Comunale, Mary Ann , Wang, Mengjun , Liang, Hongyan , Hafner, Julie, Karabudak, Aykan , Giama, Nasra H., Moser, Catherine D., Miyoshi, Eiji , Roberts, Lewis R. , Block, Timothy M. , Mehta, Anand S. , Mehta, Anand , Roberts, Lewis R

Mayo Clinic

PROTEOMICS – Clinical Applications | May 31, 2017 | Volume: 11 | Issue: 9-10 | Pages: No page available

10.1002/prca.201600141 | PMID 28561948 Get It

PurposeCholangiocarcinoma (CCA) is a malignancy of the bile ducts. The purpose of this discovery study was to identify effective serum markers for surveillance of cholangiocarcinoma.Experimental designUsing a glycomic method, patients with CCA were determined to have increased levels of alpha‐1,3 and alpha‐1,6 linked fucosylated glycan. Proteomic analysis of the serum fucosylated proteome identified proteins such as alpha‐2‐macroglobulin, kininogen, hemopexin, fetuin‐A, alpha‐1 anti‐trypsin, and ceruloplasmin as being hyperfucosylated in HCC. The levels of these glycoproteins in 109 patients with CCA, primary sclerosing cholangitis (PSC), and control patients were compared to the performance of CA‐19‐9, the current “gold standard” assay for cholangiocarcinoma.ResultsFucosylated Fetuin‐A (fc‐Fetuin‐A) had the best ability to differentiate CCA from PSC, with an AUROC of 0.812 or 0.8665 at differentiating CCA from those with PSC or other liver disease. CA‐19‐9 had poor ability to differentiate PSC from cholangiocarcinoma (AUROC of 0.625).Conclusion and clinical relevanceUsing glycomic and proteomic methods we identified a set of proteins that contain altered glycan in the sera of those with CCA. One of these proteins, fucosylated Fetuin‐A may have value in the surveillance of people at risk for the development of cholangiocarcinoma.
Tumor Progression Following Petroclival Meningioma Subtotal Resection: A Volumetric Study
Hunter, Jacob B. , O’Connell, Brendan P., Carlson, Matthew L. , Chambless, Lola, Yawn, Robert J. , Mistry, Akshitkumar M. , Thompson, Reid C., Weaver, Kyle D., Wanna, George B. , Wang, Ray , Hunter, Jacob B

Mayo Clinic

Operative Neurosurgery | May 24, 2017 | Volume: 14 | Issue: 3 | Pages: 215-223

10.1093/ons/opx098 | PMID 28541487 Get It

Abstract BACKGROUND One study has investigated postoperative growth rates following subtotal resection of petroclival meningiomas utilizing linear measurements, which are insensitive to the multidimensional complex growth of meningiomas, to estimate tumor volume. OBJECTIVE To describe petroclival meningioma growth patterns following less-than-complete resection utilizing volumetric analysis and to identify variables associated with tumor progression. METHODS Patients with surgically resected WHO grade I petroclival meningiomas were retrospectively reviewed (1999-2015). Image analysis software was utilized to perform volumetric analyses of tumor size and growth on serial MRI studies. The impact of preoperative and postoperative variables on tumor growth after subtotal resection was analyzed. An increase in tumor volume of at least 20% was defined as “tumor growth.” RESULTS Twenty-three patients had immediate preoperative and serial postoperative MRI studies available for review. The mean preoperative tumor volume was 20.9 cm 3 (range 0.4-54.6). The mean extent of resection was 75.5% (range 31.5%-100.0%). At a mean follow-up of 24.8 mo, 12 tumors (66.7%) exhibited radiological tumor growth, while 6 tumors did not change in size. The median annual volumetric growth rate was 2.82 cm 3 /yr (range –0.34 to 10.1). Extent of resection and immediate postoperative tumor volume were significantly correlated with the annual volumetric growth rate following resection. At last follow-up, 3 (13%) patients required further intervention. CONCLUSION The majority of petroclival meningiomas exhibit growth following subtotal resection. Extent of resection is strongly associated with risk for disease progression following surgery.
Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia
Papaioannou, Dimitrios , Shen, Changxian , McNeil, Betina, Bill, Marius , Karunasiri, Malith, Burke, Matthew H. , Özer, Hatice Gülçin , Yilmaz, Selen, Zitzer, Nina C. , Behbehani, Gregory K. , Oakes, Christopher C. , Steiner, Damian J., Marcucci, Guido , Powell, Bayard L., Kolitz, Jonathan E. , Carter, Thomas H. , Wang, Eunice S. , Mrózek, Krzysztof , Bloomfield, Clara D. , Garzon, Ramiro , Dorrance, Adrienne M. , Nicolet, Deedra , Wang, Eunice S. , Croce, Carlo Maria , Caligiuri, Michael A.

Mayo Clinic

Proceedings of the National Academy of Sciences | May 22, 2017 | Volume: 114 | Issue: 23 | Pages: No page available

10.1073/pnas.1703142114 | PMID 28533390 Get It

Significance In this work we report on the previously uncharacterized clinical and biological role for EGFL7 in acute myeloid leukemia (AML). Patients with increased EGFL7 mRNA expression had lower complete remission rates and shorter overall and event-free survival, demonstrating the clinical relevance of EGFL7 expression in cytogenetically normal AML. Our results show that AML blasts are able to synthesize and secrete EGFL7 protein, promoting autocrine blast cell growth. Inhibition of EGFL7 results in decreased proliferation and induces apoptosis of AML cells. Taken together, our data provide the rationale for targeting EGFL7 using blocking antibodies as a therapy for patients with AML.
Polycystic Kidney Disease without an Apparent Family History
Iliuta, Ioan-Andrei, Kalatharan, Vinusha , Wang, Kairong , Gall, Émilie Cornec-Le , Conklin, John , Pourafkari, Marina, Borgo, Alessia C., He, Ning , Song, Xuewen , Heyer, Christina M., Senum, Sarah R. , Paterson, Andrew D. , Harris, Peter C. , Khalili, Korosh , Pei, York , Cornec-Le Gall, Emilie, Ting, Ryan S. , Chen, Chen , Hwang, Young‐Hwan , Harris, Peter C , Paterson, Andrew , Senum, Sarah R , Cornec-Le Gall, Emilie

Mayo Clinic

Journal of the American Society of Nephrology | May 18, 2017 | Volume: 28 | Issue: 9 | Pages: 2768-2776

10.1681/asn.2016090938 | PMID 28522688 Get It

The absence of a positive family history (PFH) in 10%–25% of patients poses a diagnostic challenge for autosomal dominant polycystic kidney disease (ADPKD). In the Toronto Genetic Epidemiology Study of Polycystic Kidney Disease, 210 affected probands underwent renal function testing, abdominal imaging, and comprehensive PKD1 and PKD2 mutation screening. From this cohort, we reviewed all patients with and without an apparent family history, examined their parental medical records, and performed renal imaging in all available parents of unknown disease status. Subsequent reclassification of 209 analyzed patients revealed 72.2% (151 of 209) with a PFH, 15.3% (32 of 209) with de novo disease, 10.5% (22 of 209) with an indeterminate family history, and 1.9% (four of 209) with PFH in retrospect. Among the patients with de novo cases, we found two families with germline mosaicism and one family with somatic mosaicism. Additionally, analysis of renal imaging revealed that 16.3% (34 of 209) of patients displayed atypical PKD, most of which followed one of three patterns: asymmetric or focal PKD with PFH and an identified PKD1 or PKD2 mutation (15 of 34), asymmetric and de novo PKD with proven or suspected somatic mosaicism (seven of 34), or focal PKD without any identifiable PKD1 or PKD2 mutation (eight of 34). In conclusion, PKD without an apparent family history may be due to de novo disease, missing parental medical records, germline or somatic mosaicism, or mild disease from hypomorphic PKD1 and PKD2 mutations. Furthermore, mutations of a newly identified gene for ADPKD, GANAB , and somatic mosaicism need to be considered in the mutation-negative patients with focal disease.
Brain-derived neurotrophic factor and airway fibrosis in asthma
Freeman, Michelle, Sathish, Venkatachalem , Manlove, L., Wang, Shengyu , Britt, Rodney D. , Prakash, Y. S. , Freeman, Michelle R, Manlove, Logan, Prakash, Y S , Thompson, Michael A. , Pabelick, Christina M. , Sathish, Venkatachalem

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | May 18, 2017 | Volume: 313 | Issue: 2 | Pages: L360-L370

10.1152/ajplung.00580.2016 | PMID 28522569 Get It

Airway remodeling in asthma driven by inflammation involves proliferation of epithelial cells and airway smooth muscle (ASM), as well as enhanced extracellular matrix (ECM) generation and deposition, i.e., fibrosis. Accordingly, understanding profibrotic mechanisms is important for developing novel therapeutic strategies in asthma. Recent studies, including our own, have suggested a role for locally produced growth factors such as brain-derived neurotrophic factor (BDNF) in mediating and modulating inflammation effects. In this study, we explored the profibrotic influence of BDNF in the context of asthma by examining expression, activity, and deposition of ECM proteins in primary ASM cells isolated from asthmatic vs. nonasthmatic patients. Basal BDNF expression and secretion, and levels of the high-affinity BDNF receptor TrkB, were higher in asthmatic ASM. Exogenous BDNF significantly increased ECM production and deposition, especially of collagen-1 and collagen-3 (less so fibronectin) and the activity of matrix metalloproteinases (MMP-2, MMP-9). Exposure to the proinflammatory cytokine TNFα significantly increased BDNF secretion, particularly in asthmatic ASM, whereas no significant changes were observed with IL-13. Chelation of BDNF using TrkB-Fc reversed TNFα-induced increase in ECM deposition. Conditioned media from asthmatic ASM enhanced ECM generation in nonasthmatic ASM, which was blunted by BDNF chelation. Inflammation-induced changes in MMP-2, MMP-9, and tissue inhibitor metalloproteinases (TIMP-1, TIMP-2) were reversed in the presence of TrkB-Fc. These novel data suggest ASM as an inflammation-sensitive source of BDNF within human airways, with autocrine effects on fibrosis relevant to asthma.